ORGO FY2025 SEC EDGAR DEF 14A #135 of 168 in industry

Organogenesis Holdings Inc. CEO pay ratio

The CEO earned $6.8M in FY2025 against median worker pay of $411,028 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
DE
Filing date
2026-04-30
Industry
Chemicals & Pharmaceuticals
Industry rank
#135/168

Data updated August 2026

Subscribe to Organogenesis Holdings Inc. CEO pay filing updates (RSS)

CEO-to-worker pay ratio
17:1
Below Average (Scale: 0–1000:1)
CEO pay
$6.8M
Median worker
$411,028

Answer first

Organogenesis Holdings Inc.'s FY2025 CEO total of $6.8M ranks #782 of 1,423 complete filings; its 17:1 pay ratio ranks #1238. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $411,028. Industry placement uses the FY2025 SIC-28 peer cohort (# 135 of 168, 20th percentile - among the lower quartile of industry peers by pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#782
$6.8M of 1,423 FY2025
Ratio rank
#1238
17:1 of 1,423
Industry pct
20th
among the lower quartile of industry peers by pay ratio

How Organogenesis Holdings Inc. ranks nationally

Organogenesis Holdings Inc. CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$6,811,754 45th percentile higher than 45% of 1,423 companies

$0–$2,500,000: 304 companies (21%). Below this entry. $2,500,000–$5,000,000: 182 companies (13%). Below this entry. $5,000,000–$7,500,000: 208 companies (15%). This entry sits in this band. $7,500,000–$10,000,000: 192 companies (13%). Above this entry. $10,000,000–$12,500,000: 139 companies (10%). Above this entry. $12,500,000–$15,000,000: 91 companies (6%). Above this entry. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Organogenesis Holdings Inc. vs. Chemicals & Pharmaceuticals peers

CEO total pay ($6.8M) against pay ratio (17:1) for Organogenesis Holdings Inc. (marked) and its 5 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both02690243.95380487.88070731.710760975.615.8:122.6:129.5:136.4:143.3:1CEO total payPay ratio (CEO : median worker)Organogenesis Holdings Inc., CEO total pay: 6811754 · Pay ratio (CEO : median worker): 17:1Organogenesis Holdings Inc.Intellia Therapeutics, Inc., CEO total pay: 5117748 · Pay ratio (CEO : median worker): 17:1Intellia Therapeutics, Inc.Agios Pharmaceuticals, Inc., CEO total pay: 5456520 · Pay ratio (CEO : median worker): 18:1Agios Pharmaceuticals, Inc.Aurinia Pharmaceuticals Inc., CEO total pay: 320246 · Pay ratio (CEO : median worker): 18:1Aurinia Pharmaceuticals Inc.Disc Medicine, Inc., CEO total pay: 10263798 · Pay ratio (CEO : median worker): 18:1Disc Medicine, Inc.Syndax Pharmaceuticals Inc, CEO total pay: 7281788 · Pay ratio (CEO : median worker): 19:1Syndax Pharmaceuticals Inc
Organogenesis Holdings Inc. vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Organogenesis Holdings Inc.'s structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · Organogenesis Holdings Inc.

Complete DEF 14A pay-ratio filings for this CIK across FY2022–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
17:1
FY2025
vs prior FY
-14:1
from FY2024 31:1
CEO $ YoY
-2.6%
$6.8M latest
Filings shown
4
FY2022–2025
Organogenesis Holdings Inc. CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2022 $6.0M - $131,459 46:1 -
2023 $6.2M +3.9% $362,200 17:1 -29:1
2024 $7.0M +12% $222,778 31:1 +14:1
2025 $6.8M -2.6% $411,028 17:1 -14:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1661181, FY2022–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
17:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$6.8M
Companies in Industry
168
vs. Industry Median
Below
#135 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Organogenesis Holdings Inc.: near-parity Item 402(u) ratio

Organogenesis Holdings Inc.'s FY2025 ratio 17:1 ranks #135 of 168 Chemicals & Pharmaceuticals filers (20th percentile). the CEO earned 17× the median employee ($411,028) in FY2025.

At $411,028 median worker pay, the FLOOR stamp is near pay-parity territory under HEAVY CEO total.

CEO Total Pay

$6.8M

FY2025 Summary Compensation, below median

Pay Ratio

17:1

Below typical

Organogenesis Holdings Inc. in the lower Chemicals & Pharmaceuticals third

Organogenesis Holdings Inc.'s FY2025 ratio 17:1 ranks #135 of 168 Chemicals & Pharmaceuticals filers (20th percentile). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Organogenesis Holdings Inc.'s $6.8M CEO total is at or below the $7.9M industry median CEO pay.

Dollar rank #782 and ratio rank #1238 split - treat 17:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$6.8M
Median Employee Pay
$411,028
Pay Ratio
17:1
Filing Date
2026-04-30

Company Info

Ticker
ORGO
CIK
1661181
Industry
Chemicals & Pharmaceuticals
SIC Code
2834
State
DE
View SEC filings →
SEC EDGAR DEF 14A for CIK 1661181, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Organogenesis Holdings Inc.'s FY2025 ratio 17:1 ranks #135 of 168 Chemicals & Pharmaceuticals filers (20th percentile).

Read with Organogenesis Holdings Inc.

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps FLOOR · HEAVY · ELITE-MED.

Calumet, Inc. /DE · HEAVY

ABS(ceo_total_comp) peer at $6.8M (Δ $12K lighter vs Organogenesis Holdings Inc.); FLOOR · HIGH-MED vs this page's FLOOR · HEAVY · ELITE-MED.
Eastman Kodak Co · HEAVY

ABS(ceo_total_comp) peer at $6.8M (Δ $13K heavier vs Organogenesis Holdings Inc.); MID · PAR-MED vs this page's FLOOR · HEAVY · ELITE-MED.
Rocket Lab Corp · HEAVY

ABS(ceo_total_comp) peer at $6.8M (Δ $19K heavier vs Organogenesis Holdings Inc.); MID · HIGH-MED vs this page's FLOOR · HEAVY · ELITE-MED.
Otter Tail Corp · HEAVY

ABS(ceo_total_comp) peer at $6.8M (Δ $19K lighter vs Organogenesis Holdings Inc.); MID · HIGH-MED vs this page's FLOOR · HEAVY · ELITE-MED.
Intellia Therapeutics, Inc. (SIC 28 pole)

Intellia Therapeutics, Inc. stamps FLOOR · MID$ nearest in-SIC by ABS(pay_ratio) to Organogenesis Holdings Inc.'s FLOOR filing.
National dual ranks · #782/#1238

Organogenesis Holdings Inc.'s FY2025 package sits #782 by CEO dollars and #1238 by ratio under HEAVY · FLOOR.
Ratio primer · FLOOR

Organogenesis Holdings Inc.'s FLOOR stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Organogenesis Holdings Inc. (CIK 1661181), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.